



Pharmaceuticals Division: Overview Development Portfolio (as of May 27th, 2022)

Phase I (20)	Phase II (12)	Phase III (10)
Elimusertib (ATR Inhibitor)	Regorafenib (combi Nivolumab) /// Solid tumors (recurrent or metastatic)	Darolutamide (AR Inhibitor) /// Prostate Cancer (mHSPC) (<i>ARANOTE</i>) /// Adjuvant Prostate Cancer (<i>DASL-HiCaP</i>)
SLFN12 Complex-Inducer	Regorafenib (combi Pembrolizumab) /// Hepatocellular Carcinoma (HCC)	Copanlisib (PI3K Inhibitor) /// Non-Hodgkin Lymphoma (<i>CHRONOS-4</i>)
mEGFR Inhibitor	Asundexian (FXIa Inhibitor) /// Stroke Prevention in Atrial Fibrillation (<i>PACIFIC-AF</i>) /// 2 ^o Stroke Prevention (<i>PACIFIC-STROKE</i>) /// Major Adverse Cardiac Events Prevention (<i>PACIFIC-AMI</i>)	Regorafenib (multi-Kinase Inhibitor) /// Glioblastoma (<i>GBM AGILE</i>)
²²⁷ Th-Pelgifatamab Corixetan (PSMA-Targeted Thorium Conjugate)	Fesomersen (FXI-LICA) /// Thrombosis Prevention in ESRD (<i>RE-THINC ESRD</i>)	Finerenone (MR Antagonist) /// Heart Failure (HFmr/pEF) (<i>FINEARTS-HF</i>) /// Non-diabetic CKD (<i>FIND-CKD</i>)
HER2-TTC (HER2-Targeted Thorium Conjugate)	Osocimab (anti-FXIa Antibody) /// Thrombosis Prevention in ESRD (<i>CONVERT ESRD</i>)	Vericiguat (sGC Stimulator) /// Heart Failure (HFref) (<i>VICTOR*</i>)
Bapoptulimab (ILDR2 fb Antibody)	Runcaciguat (sGC Activator) /// Chronic Kidney Disease (CKD) (<i>CONCORD</i>) /// Non-prolif. Diabetic Retinopathy (NPDR) (<i>NEON-NPDR</i>)	Elinzanetant (Neurokinin-1,3 Rec Antagonist) /// Vasomotor Symptoms (<i>OASIS</i>)
AhR Inhibitor	Adrenomedullin Pegol (PEG-ADM) /// Acute Resp. Distress Syn. (ARDS) (<i>SEAL TRIAL</i>)	Aflibercept 8MG /// Diabetic Macular Edema (DME) (<i>PHOTON**</i>) /// Neovasc. Age-rel. Macular Degen. (nAMD) (<i>PULSAR</i>)
Congestive Heart Failure Gene Therapy	BDKRB1 Receptor Antagonist /// Neuropathic Pain (<i>BRADiNP</i>)	
Mosliciguat (sGC Activator)	High Relativity Contrast Agent (HRCA) /// Magnetic Resonance Imaging (<i>HRCA-PAT</i>)	
Enuvaptan (Vasopressin V1a Receptor Antagonist)		
sGC Activator 4		
P2X4 Antagonist		
BDKRB1 Receptor Antagonist		
Peboctocogene Camaparvovec (FVIII Gene Therapy)		
Pompe Disease Gene Therapy		
Parkinson's Disease Gene Therapy		
Parkinson's Disease Cell Therapy		
sGC Activator 3		
ADRA2C Antagonist		
Zabedoseritib (IRAK4 Inhibitor)		

* Conducted by Merck & Co.

** Conducted by Regeneron Pharmaceuticals

Selection of major Pharma development portfolio projects in clinical Phase I to III

- ONCOLOGY
- WOMEN'S HEALTH
- CARDIOVASCULAR DISEASES
- OTHERS